BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Sanyou Bio and Yugong Bio Forge Strategic Alliance to Advance High-End Synthetic Molecular Enzymes

Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step ...

November 12, 2025 | News

Leucid Bio Reports Proof-of-Concept for LEU011 CAR-T Therapy in Solid Tumours from Ongoing AERIAL Trial

Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours LEU011 has been well tolerated, with disease control obser...

November 11, 2025 | News

Simcere Advances Treg-Selective IL-2 Mutant SIM0278 into Phase II Trial for Moderate-to-Severe Atopic Dermatitis

Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells (Treg) -preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278,...

November 11, 2025 | News

Muna Therapeutics Doses First Subjects in Phase 1 Trial of TREM2 Agonist MNA-001 for Alzheimer’s Disease

MNA-001 has best-in-class potential based on preclinical data demonstrating ability to significantly reduce neurotoxic amyloid burden and reprogram microgl...

November 11, 2025 | News

Akeso Initiates First-in-Human Trial of Personalised mRNA Vaccine AK154 for Pancreatic Cancer

Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vacc...

November 11, 2025 | News

Takeda’s Mezagitamab Shows Sustained Kidney Function and Proteinuria Reduction Through 18-Month Follow-Up in IgA Nephropathy

Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 ...

November 10, 2025 | News

PolyActiva and RareSight Forge Strategic Partnership to Develop Sustained-Release Therapies for Rare Pediatric Retinal Diseases

Partnership Leverages PolyActiva’s PREZIA™ Drug Delivery Platform Technology and RareSight’s Expertise in Rare Diseases to Advance Nove...

November 07, 2025 | News

Tenpoint Therapeutics and Zhaoke Ophthalmology Advance BRIMOCHOL™ PF Toward Global Market with NDA Filing in South Korea

Submission of New Drug Application (NDA) in South Korea by Zhaoke Ophthalmology Ltd.’s local partner, Kwangdong Pharmaceutical Co., Ltd., marks the...

November 07, 2025 | News

NEXT Oncology Expands to Japan Through Partnership with Kansai Medical University

With continued global expansion, NEXT Oncology is one of the world’s largest Phase I Cancer Trial organizations. NEXT Oncology, an Avac...

November 07, 2025 | News

Takeda’s QDENGA Trial Confirms Sustained Protection and Favourable Safety Over Seven Years

Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule QDENGA is the Longest-Studied Dengue Vaccine and the ...

November 06, 2025 | News

iLeukon’s mRNA IL-2 Therapy ILKN421H Achieves 80% Response Rate in Lung Cancer Trial

ILKN421H is a novel lipid nanoparticle (LNP)-formulated mRNA encoding a non-alpha HSA–IL-2v fusion protein and dominantly expressed in lymphoid org...

November 05, 2025 | News

AVEO and HiberCell Partner to Develop First-in-Human PERK Inhibitor for Kidney Cancer

First-in-Human PERK inhibitor (HC-5404) to be developed in combination with AVEO's FOTIVDA® (tivozanib) for RCC – – AVEO...

November 05, 2025 | News

Bio-Techne and Nucleai Demonstrate Predictive Power of Spatial Biomarkers in Melanoma

Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomar...

November 05, 2025 | News

Akeso Secures Fourth Breakthrough Therapy Designation for Ivonescimab in Combination Therapy for Triple-Negative Breast Cancer

Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for fi...

November 04, 2025 | News

Stay Connected